FG-3246 is under clinical development by FibroGen and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FG-3246’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FG-3246 overview
It was under development for the treatment of relapsed and refractory multiple myeloma.
FibroGen overview
FibroGen is a biopharmaceutical company primarily engaged in the development and commercialization of novel therapeutics for cancer biology and anemia. The company’s main activities involve conducting clinical trials, advancing research, and in-licensing new product candidates. FibroGen’s major products include Pamrevlumab, a first-in-class antibody targeting connective tissue growth factor (CTGF), and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase. The company’s products are primarily used in the treatment of life-threatening conditions such as metastatic pancreatic cancer, locally advanced pancreatic cancer (LAPC), and anemia associated with chronic kidney diseases. The company collaborates with partners like AstraZeneca and Fortis Therapeutics for the development and distribution of its products. FibroGen operates globally, with a significant presence in China, Europe, Japan, and other countries. FibroGen is headquartered in San Francisco, California, USA.
For a complete picture of FG-3246’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
